Asia Pacific Neurological Biomarker Market

Market Introduction

Neurological biomarkers are molecules present in the cerebral spinal fluid (CSF) or blood that support the diagnosis of brain disorders and monitor disease progression. This helps in the previous detection of disease, less invasive diagnostics, allows faster drug development, and is expected to be the effective treatment.

Asia Pacific Neurological Biomarker Strategic Insights

Strategic insights for the Asia Pacific Neurological Biomarker provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Neurological Biomarker Report Scope

Asia Pacific Neurological Biomarker Regional Insights

The geographic scope of the Asia Pacific Neurological Biomarker refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Asia Pacific neurological biomarker market is expected to reach US$ 2,620.63 million by 2027 from US$ 927.05 million in 2019; it is estimated to grow at a CAGR of 14.1% from 2020 to 2027. The growth of the market is attributed to key driving factors such as rising prevalence of neurological diseases and growing focus on neurological biomarker research. On the other hand, concerns associated with use of biomarkers such as the absence of pre-analytical tests are among the major factors hindering the market growth.

Key Market Segments

The Asia Pacific neurological biomarker market, based on product, is segmented into proteomics biomarker, genomics biomarker, metabolomics biomarker, imaging biomarker, and others. In 2019, the genomics biomarker segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest rate during the forecast period.

Based on application, the Asia Pacific neurological biomarker market is segmented into Alzheimer’s disease, Parkinson's disease, schizophrenia, Huntington's disease, spinal muscular atrophy, and others. The Alzheimer’s disease segment held the largest market share in 2019, and the market for the same segment is anticipated to grow at a significant rate during 2020 –2027.

The Asia Pacific neurological biomarker market, by end user, is segmented into pharmaceutical and biotechnology companies, clinical diagnostics, and research organizations. In 2019, the pharmaceutical and biotechnology companies segment held the largest share of the market. In addition, the market for the same segment is expected to grow at the fastest rate from 2020 to 2027.

Major Sources and Companies Listed

A Few of the primary and secondary sources associated with this report on the Asia Pacific neurological biomarker market are the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) and Biomarkers Across Neurodegenerative Diseases (BAND).

Reasons to buy the report

• Determine prospective investment areas based on a detailed trend analysis of the Asia Pacific neurological biomarker market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
• Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels driving the Asia Pacific neurological biomarker market, providing a clear picture of future opportunities that will help Analyze, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Asia Pacific neurological biomarker market.

ASIA PACIFIC NEUROLOGICAL BIOMARKER SEGMENTATION

By Product

• Proteomics Biomarker
• Genomics Biomarker
• Metabolomics Biomarker
• Imaging Biomarker
• Others

By Application

• Alzheimer’s Disease
• Parkinson's Disease
• Schizophrenia
• Huntington's Disease
• Spinal Muscular Atrophy
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Clinical Diagnostics
• Research Organizations

By Country

• India
• China
• Australia
• South Korea
• Japan
• Rest of Asia Pacific

Company Profiles

• Thermo Fisher Scientific Inc.
• Abbott
• Bio-Rad Laboratories Inc.
• QIAGEN
• Immunarray Pvt. Ltd.
• Quest Diagnostics Incorporated
• Perkin Elmer, Inc
• MERCK KGaA